.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Medtronic
Mallinckrodt
Cipla
McKesson
Moodys
Colorcon
AstraZeneca
McKinsey

Generated: January 19, 2018

DrugPatentWatch Database Preview

Patents Expiring in November 2032

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences IncVOSEVIsofosbuvir; velpatasvir; voxilaprevirTABLET;ORAL209195-001Jul 18, 2017RXYesYes➤ Subscribe➤ SubscribeYY
Gilead Sciences IncEPCLUSAsofosbuvir; velpatasvirTABLET;ORAL208341-001Jun 28, 2016RXYesYes➤ Subscribe➤ SubscribeYYFOR THE TREATMENT OF HEPATITIS C
Gilead Sciences IncEPCLUSAsofosbuvir; velpatasvirTABLET;ORAL208341-001Jun 28, 2016RXYesYes➤ Subscribe➤ SubscribeYYFOR THE TREATMENT OF HEPATITIS C
Gilead Sciences IncEPCLUSAsofosbuvir; velpatasvirTABLET;ORAL208341-001Jun 28, 2016RXYesYes➤ Subscribe➤ SubscribeYYFOR THE TREATMENT OF HEPATITIS C
Gilead Sciences IncVOSEVIsofosbuvir; velpatasvir; voxilaprevirTABLET;ORAL209195-001Jul 18, 2017RXYesYes➤ Subscribe➤ SubscribeYY
Pf Prism CvTORISELtemsirolimusSOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes➤ Subscribe➤ SubscribeY
Alkermes IncARISTADAaripiprazole lauroxilSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207533-004Jun 5, 2017RXYesNo➤ Subscribe➤ SubscribeYTREATMENT OF SCHIZOPHRENIA
Alkermes IncARISTADAaripiprazole lauroxilSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207533-003Oct 5, 2015RXYesYes➤ Subscribe➤ SubscribeYTREATMENT OF SCHIZOPHRENIA
Alkermes IncARISTADAaripiprazole lauroxilSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207533-002Oct 5, 2015RXYesNo➤ Subscribe➤ SubscribeYTREATMENT OF SCHIZOPHRENIA
Alkermes IncARISTADAaripiprazole lauroxilSUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR207533-001Oct 5, 2015RXYesNo➤ Subscribe➤ SubscribeYTREATMENT OF SCHIZOPHRENIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Covington
US Department of Justice
Cipla
US Army
Boehringer Ingelheim
McKesson
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot